Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy by  et al.
  
 University of Groningen
Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-
forward loop between LXR and autophagy
IMPROVE Study Grp; Saliba-Gustafsson, P.; Pedrelli, M.; Gertow, K.; Werngren, O.; Janas,
V.; Pourteymour, S.; Baldassarre, D.; Tremoli, E.; Veglia, F.
Published in:
Journal of Internal Medicine
DOI:
10.1111/joim.12951
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
IMPROVE Study Grp, Saliba-Gustafsson, P., Pedrelli, M., Gertow, K., Werngren, O., Janas, V., ...
Ehrenborg, E. (2019). Subclinical atherosclerosis and its progression are modulated by PLIN2 through a
feed-forward loop between LXR and autophagy. Journal of Internal Medicine.
https://doi.org/10.1111/joim.12951
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
doi: 10.1111/joim.12951
Subclinical atherosclerosis and its progression are
modulated by PLIN2 through a feed-forward loop between
LXR and autophagy
P. Saliba-Gustafsson1,2 , M. Pedrelli3 , K. Gertow1, O. Werngren1, V. Janas1, S. Pourteymour1,
D. Baldassarre4,5, E. Tremoli5,6, F. Veglia5, R. Rauramaa7, A.J. Smit8, P. Giral9, S. Kurl10 , M. Pirro11, U.de Faire12,
S.E. Humphries13, A. Hamsten1, on behalf of the IMPROVE Study Group,‡, I. Goncalves14, M. Orho-Melander15,
A. Franco-Cereceda16, J. Boren17 , P. Eriksson1 , J. Magne1,18,†, P. Parini3,19,† & E. Ehrenborg1,†
From the, 1Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine at BioClinicum, Karolinska University
Hospital, Karolinska Institutet, Stockholm, Sweden; 2Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California,
USA; 3Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet Huddinge, Huddinge, Sweden; 4Department
of Medical Biotechnology and Translational Medicine, Universita degli Studi di Milano; 5Centro Cardiologico Monzino, IRCCS; 6Dipartimento
di Scienze Farmacologiche e Biomolecolari, Universita di Milano, Milan, Italy; 7Foundation for Research in Health Exercise and Nutrition,
Kuopio Research Institute of Exercise Medicine, Kuopio, Finland; 8Department of Medicine, University Medical Center Groningen, Groningen,
The Netherlands; 9Assistance Publique Hopitaux de Paris, Service Endocrinologie-Metabolisme, Groupe Hospitalier Pitie-Salpetriere, Unites
de Prevention Cardiovasculaire, Paris, France; 10Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio,
Finland; 11Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Perugia, Italy;
12Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 13Centre for
Cardiovascular Genetics, Institute Cardiovascular Science, University College London, London, UK; 14Experimental Cardiovascular Research
Group and Cardiology Department, Clinical Research Center, Clinical Sciences Malm€o; 15Department of Clinical Sciences in Malm€o, Lund
University Diabetes Centre, Lund University, Lund; 16Cardiothoracic Surgery Unit, Department of Molecular Medicine and Surgery,
Karolinska Institutet at Karolinska University Hospital Solna, Solna; 17Department of Molecular and Clinical Medicine/Wallenberg
Laboratory, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden; 18St Jude Children’s Research Hospital,
Department of Immunology, Memphis, Tennessee, USA; and 19Metabolism Unit, Department of Medicine, Karolinska Institutet at Karolinska
University Hospital Huddinge, Huddinge, Sweden
Abstract. Saliba-Gustafsson P, Pedrelli M, Gertow K,
Werngren O, Janas V., Pourteymour S, Baldassarre
D,TremoliE,VegliaF,RauramaaR,SmitAJ,GiralP,
Kurl S, PirroM, de FaireU,Humphries SE,Hamsten
A, on behalf of the IMPROVE Study Group ,
Goncalves I, Orho-Melander M, Franco-Cereceda
A,BorenJ,ErikssonP,MagneJ,PariniP,Ehrenborg
E (Karolinska Institutet, Stockholm, Sweden;
Stanford University School of Medicine, Palo Alto,
CA, USA; Karolinska Institutet Huddinge,
Huddinge, Sweden; Universita degli Studi di
Milano; IRCCS; Universita di Milano, Milan, Italy;
Kuopio Research Institute of Exercise Medicine,
Kuopio, Finland; University Medical Center
Groningen, Groningen, The Netherlands; Unites de
Prevention Cardiovasculaire, Paris, France;
University of Eastern Finland, Kuopio, Finland;
University of Perugia, Perugia, Italy; Karolinska
Institutet, Stockholm, Sweden; University College
London, London, UK; Lund University, Lund;
Karolinska Institutet at Karolinska University
Hospital Solna, Solna; University of Gothenburg
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Memphis, TN, USA; Karolinska Institutet at
Karolinska University Hospital Huddinge,
Huddinge, Sweden). Subclinical atherosclerosis
and its progression are modulated by PLIN2
through a feed-forward loop between LXR and
autophagy. J Intern Med 2019; https://doi.org/10.
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Background. Hyperlipidaemia is a major risk factor for
cardiovascular disease, and atherosclerosis is the
underlying cause of both myocardial infarction and
stroke. We have previously shown that the Pro251
variant of perilipin-2 reduces plasma triglycerides
and may therefore be beneficial to reduce
atherosclerosis development.
Objective. We sought to delineate putative beneficial
effects of the Pro251 variant of perlipin-2 on
subclinical atherosclerosis and the mechanism by
which it acts.
Methods. A pan-European cohort of high-risk indi-
viduals where carotid intima-media thickness has
been assessed was adopted. Human primary
monocyte-derived macrophages were prepared
from whole blood from individuals recruited by
perilipin-2 genotype or from buffy coats from the
Karolinska University hospital blood central.
†Equal Contribution.‡See Appendix 11 for the on behalf of the
IMPROVE Study Group.
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Results. The Pro251 variant of perilipin-2 is associ-
ated with decreased intima-media thickness at
baseline and over 30 months of follow-up. Using
human primary monocyte-derived macrophages
from carriers of the beneficial Pro251 variant, we
show that this variant increases autophagy activ-
ity, cholesterol efflux and a controlled inflamma-
tory response. Through extensive mechanistic
studies, we demonstrate that increase in autop-
hagy activity is accompanied with an increase in
liver-X-receptor (LXR) activity and that LXR and
autophagy reciprocally activate each other in a
feed-forward loop, regulated by CYP27A1 and
27OH-cholesterol.
Conclusions. For the first time, we show that per-
ilipin-2 affects susceptibility to human
atherosclerosis through activation of autophagy
and stimulation of cholesterol efflux. We demon-
strate that perilipin-2 modulates levels of the LXR
ligand 27OH-cholesterol and initiates a feed-for-
ward loop where LXR and autophagy reciprocally
activate each other; the mechanism by which
perilipin-2 exerts its beneficial effects on subclin-
ical atherosclerosis.
Keywords: 27OH-cholesterol, atherosclerosis, au-
tophagy, liver-X-receptor, PLIN2.
Abbreviations: 3MA, 3-methyladenine; 27-HC, 27-hy-
droxycholesterol; CPIP, Carotid Plaque Imaging
Project; IMT, carotid intima-media thickness;
LXR, liver-X-receptor; oxLDL, oxidized low-density
lipoprotein; PLIN2, perilipin-2.
Introduction
Atherosclerotic cardiovascular disease (CVD) is the
major cause of death worldwide. The natural
history of atherosclerosis involves formation of
macrophage foam cells and subsequent lesion
formation in intermediate-size and large arteries,
characterized by lipid retention in the vessel wall,
inflammation, cell death and fibrosis [1]. Lipid
droplets (LDs) are the major site of cholesterol
storage in macrophage foam cells, and LD-associ-
ated proteins are localized on the surface of LDs.
Perilipin-2 (PLIN2) is the most abundant LD-asso-
ciated protein in macrophage foam cells [2,3] and
has been implicated in atherosclerosis since it is
highly expressed in macrophage foam cells [3] and
PLIN2 overexpression reduces cholesterol efflux
from THP-1 macrophages [4]. Furthermore,
ApoE/mice have ~3.5 times higher PLIN2 expres-
sion, and genetic depletion of PLIN2 in murine
models of atherosclerosis results in reduced plaque
burden [5]. Thus, PLIN2 is considered as a strong
and promising target to treat atherosclerosis [3,6].
Recently, we have characterized a common protein
variant in PLIN2 (Pro251), which is associated with
a less atherogenic plasma lipid profile [7], suggest-
ing that this genetic variant may modulate macro-
phage foam cell formation and affect proneness to
atherosclerosis.
The liver-X-receptor (LXR)-dependent upregulation
of cholesterol transporters and subsequent efflux of
cholesterol to extracellular acceptors are an impor-
tant process through which macrophages expel
their excess cholesterol, whichhalts atherosclerosis
[8,9]. In line with this, the ability of plasma to accept
cholesterol expelled from macrophages, designated
‘cholesterol efflux capacity’, has been shown to be
inversely associated with incidence of cardiovascu-
lar events [10]. Autophagy is another significant
contributor to cholesterol efflux from foamcells [11].
Autophagy, which previously was primarily consid-
ered a cellular homoeostatic process [12,13], has
therefore been assigned a protective role in early
atherosclerosis. Despite recent attention paid to
autophagy in atherosclerosis and CVD [14], human
data are still scarce and the relationship between
LXR and autophagy in macrophage foam cells has
never been explicitly examined.
In the present work, we sought to delineate the role
of PLIN2 in human atherosclerosis using the
Ser251Pro variant in PLIN2 as a genetic tool. We
show that PLIN2 modulates subclinical atheroscle-
rosis, macrophage foam cell formation and choles-
terol efflux by initiating a feed-forward loop where
LXRandautophagy reciprocally activate eachother.
Materials and methods
Genetic association study
The IMPROVE study (acronym for ‘carotid intima-
media thickness (IMT) and IMT progression as
predictors of vascular events in a high-risk Euro-
pean population’ study) is a pan-European, multi-
centre, longitudinal, cohort study designed to
investigate whether cross-sectional carotid IMT (C-
IMT)measurements and IMT progression are useful
predictors of cardiovascular events in European
individuals who are at high risk of CVD [15]. The
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study comprises 3711 participants, aged 54–
79 years, of whom 48% are men. Inclusion criteria
werepresentationof ≥3classical cardiovascular risk
factors andabsenceof previous events at enrolment.
All participants have undergone state-of-the-art
high-resolution carotid ultrasound examinations
following an established protocol applied at all
recruitment centres. In brief, the mean and maxi-
mum IMT measurements of the common carotid at
the first centimetre proximal to the bifurcation, the
common carotid (excluding the first centimetre
proximal to the bifurcation), the carotid bifurcation
and the internal carotid arteries were taken. IMT is
definedas the thicknessof the vesselwall,measured
from the leading edge of the lumen-intima interface
to the leading edge of themedia-adventitia interface.
Segment-specific IMT measurements were used to
generate composite IMT measurements; mean IMT,
maximum IMT and the mean of the maximum IMT.
C-IMT variables were analysed both as baseline
values and as changes over time (expressed in mm/
year), calculated, within subject, by linear regres-
sion using 3 measurements taken at 0, 15 and
30 months. All study subjects gave their informed
consent, and local ethics committees across all
countries participating in the study approved the
study. The entire cohort was genotyped for Ser251-
Pro single nucleotide polymorphism in PLIN2 using
tailored TaqMan probes as previously described [7].
Human carotid artery atherosclerotic plaques
Calculation of the % core area and CD68 staining
using immunohistochemistry was carried out in 40
human carotid atherosclerotic plaques (20 from
either variant of PLIN2, matched for age, sex and
diabetes status and treatment) from the Carotid
Plaque Imaging Project (CPIP). The CPIP biobank
includes carotid plaques from patients undergoing
carotid endarterectomies at the Skane University
Hospital, Malm€o, Sweden. The indications for
surgery were the presence of plaques associated
with ipsilateral symptoms (transient ischaemic
attack, stroke or amaurosis fugax) and stenosis
higher than 70%, or plaques not associated with
symptoms but with stenosis larger than 80% as
previously described [16]. Informed consent was
obtained from each patient, and the local ethics
review board approved the study.
Isolation of lipoproteins
Lipoproteins used for foam cell formation, as well
as for cholesterol efflux assays, were isolated
through sequential ultracentrifugation from
human plasma obtained from the Blood Central
at Karolinska University Hospital. Briefly, plasma
was ultracentrifuged for >22 h at 285,000 9 g at
4°C. The upper-most fraction containing chylomi-
crons was discarded, and the intermediate fraction
containing low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) was collected. The den-
sity of the LDL/HDL fraction was adjusted to
1.063 g/ml with potassium bromide (Sigma-
Aldrich, Stockholm, Sweden) and ultracentrifuged
as described. The upper fraction, now containing
LDL, was collected and desalted using a PD-10
column (GE Healthcare, Stockholm, Sweden). LDL
was oxidized over night at 37°C using 20 lmol L1
copper sulphate [CuSO4] (Merck), and the reaction
was stopped using 1 mmol L1 EDTA (Sigma-
Aldrich). The lower fraction containing HDL was
desalted, sterile-filtered and diluted to a concen-
tration of 2 mg/mL and used as an acceptor in
cholesterol efflux assays.
Primary Monocytes and foam cell formation assay
Primary monocytes were isolated from whole blood
of healthy individuals carrying either variant of
PLIN2 (9noncarriers and11carrierswere recruited).
The recruit-by-genotype protocol has previously
been described in detail [7]. Briefly, whole blood
was diluted 1:1 with phosphate-buffered saline and
layeredontoaFicoll-Paque (GEHealthcare) gradient
to separate monocytes/lymphocytes from red blood
cells and neutrophils by centrifugation (400 9 g,
30 min). The intermediate fraction, containing
monocytes and lymphocytes, was collected and
residual redbloodcellswere lysedusingAmmonium
Chloride–Potassium (ACK) lysis buffer (Sigma-
Aldrich). A highly pure population of monocytes
was obtained by magnetic depletion of nonmono-
cytic cells (Miltenyi Biotec, Lund, Sweden). When
assessing the relationship between LXR and autop-
hagy, monocytic cells were isolated using a hyper-
osmotic Percoll (GE Healthcare) solution and sub-
sequent centrifugation (580 9 g, 15 min).
Monocytes at a density of 350,000 cells/mL were
cultured on tissue culture plates using RPMI (+5%
foetal bovine serum and 0.1% Penicillin-Strepto-
mycin) and differentiated with macrophage colony-
stimulating factor (M-CSF) (100 ng/mL) treatment
for 7 days, boosting the cells on day 3 with
additional M-CSF. When differentiated, macro-
phages were treated with an LXR agonist
(GW3965, 10 lmol L1), an LXR antagonist
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(GSK2033, 10 lmol L1) or 25 lg/mL oxidized low-
density lipoprotein (oxLDL) for 24 h. Complete cell
culture medium with dimethyl sulphoxide (DMSO)
(in the case of GW3965 or GSK2033 treatment) or
without supplementation with oxLDL served as
control. When modulating autophagy, 2 h pre-
incubation with either a mammalian target of
rapamycin (mTOR) inhibitor (rapamycin at
200 nmol L1) or autophagy inhibitor (3-methy-
ladenine (3MA) at 5 mmol L1) was adopted, upon
which the cells were maintained in culture for
24 h. In order to monitor autophagy flux,
100 nmol L1 bafilomycin A1 was added to each
experimental condition as 2-h pretreatment as
indicated.
Human primary monocyte-derived macrophages
carrying either variant of PLIN2 were challenged
with oxLDL to generate foam cells; complete cell
culture medium without oxLDL supplementation
was used as control. Bafilomycin A1 was used to
investigate whether autophagy affects foam cell
formation. PLIN2 expression was quantified using
reverse transcription polymerase chain reaction
(RT-PCR) and Western blotting. Cholesterol ester
accumulation was determined using a colorimetric
assay and 27-hydroxycholesterol (27-HC) levels
were assessed using mass spectrometry, as
described.
Study subjects included in the recruit-by-genotype
study gave their informed consent to their partic-
ipation and the local ethics committee approved
the study (approval nr. 02-091).
RT-PCR and western blotting
RNA and protein were extracted from macrophage
foam cells using RNeasy Mini Kits according to a
modifiedmanufacturer’s protocol, with the reagents
provided (QIAGEN, Sollentuna, Sweden). After each
centrifugation, the flow-through was collected and
pooled for biological replicates and protein was
isolated from the flow-through. RNA concentration
was determined using NanoDrop 1000 (Thermo
Scientific, Stockholm, Sweden). Reverse transcrip-
tion was carried out using SuperScript III Reverse
Transcriptase (Thermo Fisher Scientific) according
to manufacturer’s instructions.
RT-PCR was carried out using TaqMan gene
expression assays (Thermo Fisher Scientific) and
StepOne Plus Real-Time PCR System (Thermo
Fisher Scientific). Relative gene expression was
determined using the Delta-Delta-CT (DDCT)
method using RPLP0 (Hs999999902_m1) as refer-
ence gene.
Protein precipitated from flow-through after stor-
age at 20°C for >48 h and protein was pelleted by
centrifugation at >15,000 g for 20 min at 4°C.
Pellets were then dissolved in 8 mol L1 urea
before Western blotting. Protein extracts were
loaded on 10% and 14% acrylamide sodium dode-
cyl sulphate–polyacrylamide gel electrophoresis
(SDS-PAGE) gels, for determination of PLIN2, p62
and LC3 protein expression. Upon migration, pro-
teins were electrophoretically transferred to
polyvinylidene difluoride membranes (BioRad,
Solna, Sweden). Membranes were blocked in 5%
milk in TBST (0.1% Tween-20 in Tris-buffered
saline) to reduce nonspecific binding. Immunoblot-
ting was carried out using anti-PLIN2, p62 and LC3
antibodies diluted 1:2000 in 5% milk, or 1:1000 in
5% BSA in the case of p62 in TBST (Origene
[Rockville, MD, USA], Santa-Cruz and BioTechne
Ltd., Oxon, England, UK, respectively). Horserad-
ish peroxidase-conjugated secondary antibodies
(1:50,000, BioRad) were used to amplify the signal.
Blots were developed using enhanced chemilumi-
nescence reagent kit (GE Healthcare) and medical
X-ray films from AGFA. ImageJ was used for
densitometry, and autophagy flux was defined as
LC3-II fold change between experimental condi-
tions supplemented with bafilomycin A1 over
experimental condition without bafilomycin A1 by
using LC-II density normalized to b-actin.
Gene expression profiling using microarrays
Gene expression profiling of monocyte-derived
macrophages andmacrophage foam cells from indi-
viduals carrying either variant of PLIN2 (n = 6) was
carried out using the Clariom D microarray from
Affymetrix. CEL files were preprocessed using
Robust Multichip Averaging (RMA) normalization,
including log2 transformation in Transcriptome
Analysis Console (TAC) from Affymetrix. All down-
streamanalyseswerecarriedout inBioconductor,R.
Inflammatory characterization of macrophage foam cells
Cytokine production profiles were used to assess
the inflammatory response of macrophage foam
cells. Cell culture medium samples were taken at
0, 6 and 24 h upon oxLDL stimulation. Multiplexed
ELISA was carried out on centrifuged medium
supernatants using the Meso-Scale Discovery
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(MSD) Proinflammatory Panel 1 (human) Kit,
simultaneously quantifying 10 cytokines (inter-
feron-c (INF-c), interleukin-1b (IL-1b), interleukin-
2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6),
interleukin-8 (IL-8), interleukin-10 (IL-10), inter-
leukin-12p70 (IL-12p70), interleukin-13 (IL-13)
and tumour necrosis factor (TNF-a)). All diluents,
calibrators and samples were prepared, and the
assay was carried out according to the manufac-
turer’s instructions.
Quantification of intracellular cholesterol and lipids
Lipids were extracted from the cell monolayers
by addition of 2 mL hexane/isopropanol
(3:2, v/v). Triglyceride (TG), total (TC) and unes-
terified cholesterol (UC) mass was measured by
enzymatic assay using commercially available kits
(Roche Diagnostics GmbH, Mannheim and Wako
Chemicals, Richmond, VA). Cell cholesterol ester
was calculated as the difference between TC and
UC content. 27-HC cholesterol levels were quanti-
fied by isotope dilution mass spectrometry as
previously described [17]. Total cell protein mass
was measured using the RC DCTM Protein Assay
(BioRad Laboratories Inc., USA) in cell monolayers
digested with 1 mol L1 NaOH.
Cholesterol efflux assay
oxLDL was labelled with 2 lCi/mL 3H-cholesterol
(Perkin Elmer). Monocyte-derived macrophages
were loaded with 3H-oxLDL in RPMI medium (+1
%FBS and 0.1% PEST) for 24 h. Cells were equi-
librated for 2 h with 0.5 mL RPMI medium without
or with the supplementation of 100 ng/mL bafilo-
mycin A1 to inhibit autophagy. After equilibration,
cells were washed 3 9 1 mL and 0.3 mL RPMI
medium containing the indicated acceptor (20 lg/
mL ApoA-1 (Tebu-bio) or 1 % total human serum)
was added. As control, only RPMI medium without
a cholesterol acceptor was used. Efflux was mea-
sured over 24 h, after which, the medium was
collected from each well and the cells were lysed
with 300 lL 0.1 mol L1 NaOH. The collected
medium and cell lysates were centrifuged at
16,000 9 g for 10 min, and cholesterol efflux was
determined by scintillation counting.
Protein mass of the cell lysates was determined
using the micro Bradford assay in accordance with
the manufacturer’s instructions (BioRad). Choles-
terol efflux data are adjusted to total protein
content in cell lysates (% Efflux/lg Protein).
Human embryonic kidney cells
Human embryonic kidney 293 (HEK293) cells were
transfected with human PLIN2 constructs contain-
ing either the major allele sequence (Ser251) or the
minor allele sequence (Pro251) using lipofectamine
2000 (Thermo Fisher Scientific), as described in
detail [7]. Stable clones were selected by culturing
transfected cells with 600 lg/mL Geneticin
(Thermo Fisher Scientific) and then maintained in
50 lg/mL Geneticin. Clones were selected by
assessing PLIN2 protein expression (Western blot),
as previously described. All treatments on HEK293
cells followed stabilization of PLIN2 protein using a
lipid-loading medium containing 400 µmol L1
oleic acid.
Co-transfection of 100 ng of a 3xLXR responsive
element (LXRE) luciferase reporter and renilla
luciferase was carried out using Lipofectamine
3000 transfection reagent (Thermo Fisher Scien-
tific) as previously described [18]. Data are pre-
sented as LXRE luciferase activity normalized to
renilla luciferase.
Statistics
Genetic data were analysed using SPSS and Plink
software v.1.07 [19] to generate linear regression
models, assessing the effect of rs35568725 on
C-IMT phenotypes. Covariates included age,
sex, plasma lipid levels and multi-dimensional
scaling (MDS) dimensions 1-3 to adjust for pop-
ulation substructures over the pan-European
population.
Experimental data were plotted and analysed using
nonparametric tests in GraphPad Prism 7; all data
are either presented as mean  standard error
(SEM) or median and inter-quartile range (IQR) as
indicated. P-values <0.05 were considered signifi-
cant and multiple-testing adjustments were
applied where appropriate.
Results
PLIN2 functionality has significant consequences on subclinical
atherosclerosis and plaque formation
Since we have previously shown that the Pro251
variant of PLIN2 is associated with a more
profitable plasma lipid profile and PLIN2 initiates
murine atherosclerosis, we investigated whether
PLIN2 modulates development of human
atherosclerosis. A high-risk pan-European
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population, which had undergone high-resolution
ultrasonographic investigation of IMT in the
carotid arteries, was genotyped for the PLIN2
Ser251Pro polymorphism. The Pro251 allele was
associated with decreased carotid IMT and slower
IMT progression over 30 months compared to the
major Ser251 variant. Specifically, the Pro251
allele was moderately associated with decreased
carotid IMT measured as Mean–Max IMT at
baseline (b = 0.009, P = 0.04) and internal car-
otid (b = 0.012, P = 0.003) as well as mean
carotid artery IMT (b = 0.003, P = 0.05) over
30 months of follow-up compared to the major
Ser251 allele, Table 1. These associations were
independent of plasma lipid levels since correc-
tion for plasma lipid levels did not affect the
results.
Since larger necrotic cores and increased infiltra-
tion of CD68-positive cells are indicative of a
vulnerable plaque, core and CD68 area of carotid
atherosclerotic plaques originating from patients
undergoing carotid endarterectomy were analysed
with respect to PLIN2 genotype. Carriers of the
Pro251 variant presented with an approximately
25% reduction plaque core area and plaque CD68
content, indicating a slower growing plaque com-
pared with noncarriers (P = 0.043 and P = 0.041,
respectively), Fig. 1. These data, in concert with the
findings on carotid IMT, suggest that the Pro251
allele in PLIN2 possesses properties protective of
atherosclerosis development.
Cholesteryl ester accumulation and 27OH-cholesterol (27-HC) are
modulated by PLIN2 functionality in oxLDL-treated monocyte-derived
macrophages
We utilized the functional Ser251Pro variant in
PLIN2 as a genetic tool to investigate the mecha-
nism behind the protective effects observed on C-
IMT.
Individuals carrying either variant of PLIN2 were
recruited, and primary monocyte-derived macro-
phages were prepared from whole blood and were
treated with or without oxLDL. Independently of
Table 1 PLIN2 modulates subclinical atherosclerosis
CHR SNP Major allele Minor allele C-IMT-phenotype MAF BETA SE P
C-IMT at Baseline
9 rs35568725 Ser251 Pro251 Mean–Max IMT 0.05 0.009 0.005 0.04
9 rs35568725 Ser251 Pro251 Mean IMT 0.05 0.0103 0.006 0.07
9 rs35568725 Ser251 Pro251 Mean ICA IMT 0.05 0.0156 0.018 0.39
C-IMT change over time
9 rs35568725 Ser251 Pro251 Mean–Max IMT 0.05 0.0021 0.003 0.47
9 rs35568725 Ser251 Pro251 Mean IMT 0.05 0.003 0.002 0.05
9 rs35568725 Ser251 Pro251 Mean ICA IMT 0.05 0.012 0.004 0.003
Association of rs35568725 with C-IMT at baseline and change over time up until 30 months of follow-up in the IMPROVE
study. Chromosome (CHR); single nucleotide polymorphism (SNP); minor allele frequency (MAF); beta value for regression

















































Fig. 1 PLIN2 functionality has
significant consequences on
carotid plaque growth and
macrophage infiltration. (a) The




plaques from the Carotid
Plaque Imaging Project carrying
either variant of PLIN2,
matched for age, sex and
diabetes status. Data are
presented as median and IQR.
An autophagy-LXR loop modulates atherosclerosis / P. Saliba-Gustafsson et al.
6 ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
genotype, PLIN2 protein was undetectable in
untreated primary monocyte-derived macro-
phages, but was readily stabilized upon oxLDL
challenge, Fig. 2(a). Human primary monocyte-
derived macrophages carrying the different vari-
ants of PLIN2 had similar levels of mRNA and
protein expression of PLIN2, Fig. 2(a–c). Although
both variants show similar PLIN2 protein levels,
human primary monocyte-derived macrophages
carrying the Pro251 variant of PLIN2 showed a
50% reduction of cholesteryl ester accumulation
upon oxLDL challenge compared to macrophages
homozygous for the major variant (P = .01),
Fig. 2(d). Contrasting, macrophages carrying
Pro251 displayed more than a 2-fold increase in
27-HC levels (P = 0.03), Fig. 2(e).
Since PLIN2 is located in the crossroads of lipid
metabolism and autophagy, we investigated the
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Fig. 2 PLIN2 modulates the
availability of 27-HC and
thereby also LXR activity. (a–c)
PLIN2 expression by variant in
PLIN2 as shown by Western
blotting and qPCR. (d–e)
Cholesterol ester and 27-HC
accumulation upon oxLDL
challenge. Data are presented
as median and IQR (b, d, e),
and mean  SEM (c). See also
Fig. S1.
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of autophagy by adding bafilomycin A1 did not
alter PLIN2 expression, nor cholesteryl ester accu-
mulation, but normalized 27-HC levels in primary
monocyte-derived macrophages carrying the
Pro251 variant to the levels of Ser251, Fig. 2(b–e).
Thus, PLIN2 functionality modulates the availabil-
ity of 27-HC.
PLIN2 influences LXR activity and cholesterol efflux by autophagy in
monocyte-derived macrophages
In the light of the increased levels of 27-HC in
oxLDL-treated monocyte-derived macrophages
carrying the Pro251 allele compared to Ser251
allele, and the fact that 27-HC is an endogenous
ligand for LXR, we hypothesized that LXR activity
was influenced by the polymorphism. Significant
co-expression patterns were found between
Pro251-PLIN2 mRNA and mRNA of ABCA1 and
ABCG1. In contrast, Ser251-PLIN2 mRNA was not
co-expressed with these cholesterol transporters,
Fig. 3(a).
Because co-expression patterns do not necessarily
reflect function, cholesterol efflux to apoA1 and
total serum from monocyte-derived macrophage






















































































































































































Cholesterol efflux with 27-HC










Fig. 3 PLIN2 comprises a hub
in cholesterol metabolism by
connecting LXR activity and
autophagy. (a) LXR target co-
expression by PLIN2 variant.
(b) Cholesterol efflux without
27-HC supplementation to the
respective acceptor by protein
variant of PLIN2. (c) Cholesterol
efflux with 27-HC
supplementation to the
respective acceptor by protein
variant of PLIN2. (d) Autophagy
activity, displayed as LC3 and
p62 flux, by PLIN2 variant
using Western blotting. (e, f)
Densitometry of bands
obtained from Western blotting.
Autophagy blockade using
bafilomycin A1 was applied as
indicated. Data are presented
as mean  SEM (b), and
median and IQR (d, e).
**P < 0.01, ***P < 0.001,
****P < 0.0001. See also
Fig. S2.
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foam cells was studied. Cells carrying the Pro251
variant had approximately 2-fold higher choles-
terol efflux to apoA1 and total serum, compared to
monocyte-derived macrophages carrying the major
variant (P < 0.001, Fig. 3(b). Observed effects on
cholesterol efflux were partly dependent on intact
autophagy since deregulation of autophagy by
bafilomycin A1 supplementation ablates the bene-
ficial effects of the Pro251 variant on cholesterol
efflux to apoA1, Fig. 3(b). Ablation of the beneficial
effects of Pro251 was accomplished by supple-
menting this system with 2.5 lmol L1 27-HC,
further the effect of autophagy was diminished,
Fig. 3(c).
In line with data herein, autophagy flux was aug-
mented by ~2-fold in oxLDL-treated human primary
monocyte-derived macrophages carrying Pro251
compared to noncarrying cells, as measured by
LC3 lipidation and p62 accumulation upon bafilo-
mycin A1 supplementation (P = 0.038 and P =
0.016, respectively), Fig. 3(d–f), see also Fig. S2A.
Additionally, the immunophenotype of monocyte-
derived macrophages was assessed using a co-
expression approach as well as 10-plex electro-
chemiluminescense assay for cytokine production.
Moderate mRNA co-expression patterns were found
between the M2 markers IL10 and ARG1 and
Pro251-PLIN2, whereas 251Ser-PLIN2 was co-ex-
pressed with pro-inflammatory and phagocytic
markers IL6 and CD68. Interestingly, IL-10, gener-
ally considered an M2 marker and an anti-inflam-
matory cytokine,was increased in cell culturemedia
from oxLDL-treated monocyte-derived macro-
phages carrying Pro251 compared to Ser251. Sim-
ilarly, to cholesterol efflux, this effect on IL-10 was,
in part, dependent on intact autophagy, Fig. S2B-D.
Taken together, data suggest that PLIN2 comprises
a hub in cholesterol metabolism by connecting LXR
activity and autophagy.
PLIN2 modulates LXR activation with significant repercussions on
autophagy activity
Collectively, the Pro251 variant in PLIN2 was
associated with higher levels of 27-HC, with a
modulation of LXR target gene expression and with
increased cholesterol efflux, which were in part
dependent on intact autophagy. Hence, autophagy
may be a means by which LXR activity is fine-
tuned, through 27-HC. We thus sought to investi-
gate whether the two variants of PLIN2 presented
with different levels of LXR activation, and whether
autophagy regulates LXR activity.
Stably transfected HEK293 cells carrying either
variant of PLIN2 were transfected with a luciferase
reporter construct carrying an LXR responsive ele-
ment. Luciferase activity was investigated in
response to LXR activation and inhibition, respec-
tively. Firefly luciferase activity was readily induced
by treatment with GW3695. Analogous to previous
data herein, the responsewas significantly higher in
cells carrying Pro251 (7-fold for Pro251 vs. 2-fold for
Ser251, P < 0.05), Fig. 4(a) (solid bars). Interest-
ingly, early autophagy blockade using 3MA resulted
in a blunted response to the LXR agonist to 60% of
the activity of GW3695 treatment alone in cells
carrying Pro251 allele, Fig. 4(a) (checked bars). In
addition, LXR stimulation resulted in an ~7-fold
upregulation of CYP27A1mRNA in HEK cells carry-
ing the Pro251 variant (p = 0.0007), Fig. S3. Nota-
bly, HEK cells carrying the Pro-variant of PLIN2
presentedwith roughly 3-fold increase inautophagy
flux when LXR is activated (P = 0.01, Ser251 vs.
Pro251), an effect ablated by treating the cells with
an LXR antagonist (P = 0.96, Ser251 vs. Pro251),
Fig. 4(b,c).
To corroborate the notion that autophagy modu-
lates LXR activity, the influence of autophagy
stimulation on the activity of the LXR responsive
element was assessed. Irrespectively of genotype,
treatment with the mTOR inhibitor rapamycin
resulted in an at least 3-fold increase in lucifer-
ase activity compared to control condition
(P = 0.0035 and 0.0022 for Ser251 and Pro251,
respectively), Fig. 4(d). Differences in absolute
luciferase activity prevailed between the PLIN2
protein variants.
Crosstalk between LXR and autophagy
Human primary monocyte-derived macrophages
were treatedwith the LXR agonist or LXR antagonist
in order to determine the reciprocal influences
between LXR and autophagy in a relevant cell type.
As expected, GW3965 stimulation induced mRNA
expression of both SREBP1c and ABCA1 3.5-4-fold,
whereas LXR inhibition abolished their expression.
PLIN2 mRNA expression remained unchanged,
Fig. 5(a). Interestingly, LXR stimulation resulted in
a 2-fold increase in autophagy activity (P = 0.01),
measured as LC3 lipidation after bafilomycin A1
supplementation compared to DMSO control. LXR
inhibition using GSK2033 normalized autophagy
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activity to levels of the control (P = 0.02), Fig. 5(b).
Thus, these results suggest that LXR activity con-
trols the level of activity of autophagy in human
primary monocyte-derived macrophages.
Monocyte-derived macrophages were treated with
the mTOR inhibitor rapamycin to stimulate
autophagy activity to assess whether autophagy
per se controls the activity of LXR. LC3 lipidation
was induced 3-fold by rapamycin treatment com-
pared to DMSO-treated controls (P = 0.002),
Fig. 5(c). The induction of autophagy also resulted
in an almost 2-fold upregulation of LXR target genes
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Fig. 4 An in vitro system of HEK293 cells confirms that the functional PLIN2 protein variant modulates LXR activity. LXR
was stimulated or inhibited using GW3965 and GSK2033, and autophagy was either stimulated or inhibited as indicated.
(a) LXR luciferase activity in HEK293 cells carrying either variant of PLIN2. (b, c) Autophagy activity, displayed as LC3 flux,
in response to LXR activation. (d) LXR Luciferase activity in response to rapamycin and 3-methyladenine (3MA) treatment.
Data are presented as mean  SEM (a, d), and median and IQR (c). See also Fig. S2.
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Collectively, data indicate that LXR and autophagy
are responsible for their reciprocal activation.
Autophagy generates the endogenous LXR ligand 27-HC, which in
turn stimulates autophagy
Since rapamycin treatment upregulated CYP27A1
expression and CYP27A1 encodes the enzyme
generating 27-HC, we also investigated whether
autophagy activity regulates 27-HC content. Mono-
cyte-derived macrophages were treated with
oxLDL, rapamycin or 3MA, to stimulate foam cell
formation, activate or inhibit autophagy, respec-
tively. Treatment with oxLDL increased 27-HC
content more than 2-fold (P = 0.0004), as antici-
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Fig. 5 LXR and autophagy regulates their reciprocal activation in human primary monocyte-derived macrophages. (a)
mRNA expression of LXR targets SREBP1c and ABCA1, and PLIN2 upon manipulation of LXR activity using GW3965 and
GSK2033. (b) Autophagy activity, displayed as LC3 flux, upon manipulation of LXR activity using GW3965 and GSK2033.
(c, d) Gene expression and autophagy activity, displayed as LC3 flux, in monocyte-derived macrophages induced by
rapamycin stimulation. Data are presented as mean  SEM.
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to a 1.5-fold increase of 27-HC levels compared to
DMSO-treated control cells (P = 0.04). Autophagy
inhibition using 3MA normalized 27-HC levels to
that of DMSO treatment (P = 0.027 vs. rapamycin),
Fig. 6(a).
Treatment of monocyte-derived macrophages with
27-HC resulted in a 2-fold increase in expression of
the LXR target gene ABCA1 (P = 0.002) and a 20%
increase in SREBP1c mRNA (P = 0.0065), which
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Fig. 6 27-HC serves as a
pivotal link in the crosstalk
between LXR and autophagy in
human primary monocyte-
derived macrophages. (a) 27-
HC measurements in response






activity, displayed as LC3 flux,
upon 27-HC treatment. (d)




activity, displayed as LC3 flux,
upon CYP27A1 silencing. Data
are presented as mean  SEM.
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CYP27A1 gene expression (P = 0.002), Fig. 6(b).
Interestingly, the upregulation of LXR target genes
by 27-HC treatment was accompanied by an ~1.5-
fold increase in autophagy activity, which was
comparable to that observed in monocyte-derived
macrophages stimulated with the LXR agonist
GW3965 (P = 0.04), Fig. 6(c). Ablation of CYP27A1
mRNA expression moderately blunted the expres-
sion of ABCA1, SREBP1c and PLIN2 Fig. 6(d), which
was accompanied by an almost 70% reduction of
autophagy activity (P = 0.002, Fig. 6(e).
Consequently, CYP27A1 and 27-HC constitute an
important link in the crosstalk between LXR and
autophagy, which is regulated by PLIN2.
Discussion
For the first time, we show that the Pro251 variant
in PLIN2 is associated with decreased subclinical
atherosclerosis as well as smaller necrotic core
sizes and decreased macrophage infiltration in
advanced atherosclerotic plaques. Our data pro-
pose that PLIN2 modulates a feed-forward loop
where LXR and autophagy reciprocally activate
each other, which ultimately has repercussions on
foam cell formation, cholesterol efflux and devel-
opment of subclinical atherosclerosis progression.
The formation of macrophage foam cells, as a
result of increased cholesterol accumulation, con-
stitutes one of the initial steps in the formation and
growth of atheromatous lesions. Since PLIN2 is
central for macrophage foam cell formation and we
have previously shown that a PLIN2 variant influ-
ences plasma lipid profiles [7], we hypothesized
that the Pro251 variant in PLIN2 would affect
atherosclerosis development. Carotid IMT is an
established risk factor for future cardiovascular
events [15], and by adopting a molecular genetic
approach, we here show that PLIN2 is influencing
subclinical atherosclerosis as measured by C-IMT.
Histologically, PLIN2 has an impact on the core
area and macrophage infiltration in human carotid
plaques and collectively, past and present data
support the notion of PLIN2 modulating cardiovas-
cular risk [4,7,20].
Cholesterol efflux from macrophage foam cells
counters the expansion of atherosclerotic plaques,
and this has been suggested as a therapeutic
leverage in the treatment of atherosclerosis [21].
ABCA1 plays a key role in cholesterol efflux,
transferring phospholipids and cholesterol from
the cellular membranes to apolipoprotein A-I and
HDL particles [22,23]. The importance of this
process in human has been shown by the obser-
vation that an effective ABCA1-mediated choles-
terol efflux protects from cardiovascular events
[10]. LXR is one of the major transcriptional
regulators of ABCA1 expression [24], and LXR
deficiency leads to macrophage foam cell forma-
tion that is paralleled by increased LDL and
reduced HDL cholesterol [25]. Autophagy is
another important contributor to cholesterol efflux
from macrophage foam cells. The process mobi-
lizes LDs to lysosomes in which lysosomal acid
lipases generate free cholesterol available for
efflux from the cell [11]. Free cholesterol can be
oxidized into oxysterols; molecules that strongly
activate LXR [26]. When comparing monocyte-
derived macrophages from donors bearing the
PLIN2 Pro251-variant, to cells bearing the
Ser251-variant, they display not only increased
cholesterol efflux leading to lower cholesteryl ester
levels, but also increased levels of 27-HC, an effect
dependent on intact autophagy. Since the substi-
tution at residue 251 does not occur in the
promoter region of the PLIN2 gene, and we have
shown that human primary monocyte-derived
macrophages carrying the different variants of
PLIN2 have similar expression of PLIN2, this
suggests conserved transcriptional activation by
cholesterol/oxysterol and LXRs. The increase in
hydrolysis of cholesteryl esters brought about by
Pro251 leads to an increase of free cholesterol in
the cell, which in turn determines synthesis of 27-
HC, as free cholesterol is the substrate for 27-HC
synthesis. Deregulation of autophagy by supple-
menting bafilomycin A1 did not alter PLIN2
expression, nor cholesteryl ester accumulation,
but decreased 27-HC levels in primary monocyte-
derived macrophages carrying the Pro251 variant
to the levels of Ser251. Hence, PLIN2 seems to be
able to modulate only the synthesis of 27-HC via
autophagy, whereas the effects on the cellular
levels of cholesteryl esters seem to be independent
of autophagy.
Significant co-expression of the Pro251-PLIN2
mRNA and the expression of LXR target genes –
ABCA1 and ABCG1 – show that the ligand gen-
erated by the increased autophagy associated
with the PLIN2 Pro251 variant activates LXR.
Thus, by studying cells from individuals bearing
different PLIN2 genetic variants, we clearly
demonstrate that LXR and autophagy crosstalk.
Nevertheless, autophagy cannot entirely explain
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the differences in LXR activation and cholesterol
efflux observed between the two PLIN2 genetic
variants because its blockade only blunts the
effects, not ablates them. Our observations made
in human primary monocyte-derived macrophage
foam cells were also reproduced in another
in vitro system, using stably transfected HEK293
cells carrying either genetic variant of PLIN2. By
monitoring CYP27A1 mRNA expression, LXRE
luciferase activity and autophagy, it was also
clear that the effects on autophagy observed in
cells carrying the PLIN2 Pro251 variant were LXR-
dependent as inhibition of LXR ablated differ-
ences between the variants of PLIN2 with regards
to autophagy flux. The use of rapamycin in stably
transfected HEK293 cells determined an increase
in LXRE luciferase activity, which was dependent
on intact autophagy. The interconnection between
LXR and autophagy was also evident in human
primary monocyte-derived macrophages: (i) by
using rapamycin, a molecule that does not
directly activate LXR, which increased the expres-
sion of the LXR target gene ABCA1; (ii) by directly
stimulating LXR with GW3965, which increased
autophagy and, obviously, also the mRNA expres-
sion of SREBP1c and ABCA1; (iii) by perturbation
of CYP27A1, the gene encoding the enzyme gen-
erating the LXR ligand 27-HC, which is alone
sufficient to reduce autophagy activity. The stud-
ies with rapamycin also corroborated the concept
that synthesis of 27-HC is in part dependent of
autophagy, since its stimulation using this mTOR
inhibitor increased the expression of CYP27A1,
leading in turn to increased levels of the endoge-
nous LXR ligand 27-HC. Therefore, it seems that
autophagy and LXR reciprocally regulate each
other by a feed-forward loop through 27-HC.
Several lines of evidence suggest that both LXR and
autophagy activation are protective against CVD,
not only by modulating cholesterol metabolism but
also by modulation of macrophage immunopheno-
types, promotion of effective efferocytosis and
resolving inflammation [11–13,27–,29]. The obser-
vations that the PLIN2 Pro251 variant is associated
with increased IL-10 production and that its
expression correlates with M2 macrophage mRNA
markers further extend the notion of crosstalk
between autophagy and LXR in the modulation of
the inflammatory responses.
In summary, we demonstrate that PLIN2 modu-
lates subclinical atherosclerosis by reducing lipid
retention in the vascular wall and macrophage
infiltration. The mechanism by which these bene-
ficial effects are produced seems to be dependent
on activation of a feed-forward loop between LXR
and autophagy. Our hypothesis is supported by
mechanistic studies in monocyte-derived macro-
phage foam cells carrying different PLIN2 genetic
variants, and from an in vitro model of stably
transfected cells carrying either variant of PLIN2.
The crosstalk between LXR and autophagy is
mediated by 27-HC and has a striking impact on
foam cell formation by promoting cholesterol
efflux, decreasing cholesteryl ester accumulation
and improving macrophage immunophenotypes.
Ultimately, the intricate molecular relationship
between LXR and autophagy has repercussions
on atherosclerosis progression and deserves future
attention.
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